Advertisement

Successful Use of an Advanced Hybrid Closed-loop System in a Patient With Type 3c Pancreatogenic Diabetes Secondary to Nesidioblastosis

  • Sandra Amuedo
    Affiliations
    Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, Spain
    Search for articles by this author
  • Virginia Bellido
    Correspondence
    Address correspondence to: Virginia Bellido MD, PhD, Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Avenida Manuel Siurot s/n 41013, Sevilla, Spain.
    Affiliations
    Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, Spain

    Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain
    Search for articles by this author
  • Miguel Ángel Mangas Cruz
    Affiliations
    Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, Spain

    Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain
    Search for articles by this author
  • Noelia Gros Herguido
    Affiliations
    Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, Spain

    Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain
    Search for articles by this author
  • Gema López Gallardo
    Affiliations
    Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, Spain
    Search for articles by this author
  • Ana Pérez Morales
    Affiliations
    Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, Spain
    Search for articles by this author
  • Alfonso Soto Moreno
    Affiliations
    Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, Spain

    Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain

    Facultad de Medicina, Departamento de Medicina, Universidad de Sevilla, Sevilla, Spain
    Search for articles by this author
Published:September 17, 2022DOI:https://doi.org/10.1016/j.jcjd.2022.09.117
      Nesidioblastosis is a rare pancreatic disease, characterized by hypoglycemia due to endogenous hyperinsulinism. It results from abnormal proliferation of pancreatic islet cells in the absence of an insulinoma. Nesidioblastosis usually occurs in neonates or in childhood and is rare in adults. Hyperglycemic drugs, such as diazoxide or octreotide, are the first therapeutic option, although their efficacy is limited. In severe cases of nesidioblastosis, pancreatectomy may be required (
      • Kowalewski A.M.
      • Szylberg Ł.
      • Kasperska A.
      • Marszałek A.
      The diagnosis and management of congenital and adult-onset hyperinsulinism (nesidioblastosis)---literature review.
      ,
      • Makuc J.
      Management of pancreatogenic diabetes: Challenges and solutions.
      ).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Diabetes
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kowalewski A.M.
        • Szylberg Ł.
        • Kasperska A.
        • Marszałek A.
        The diagnosis and management of congenital and adult-onset hyperinsulinism (nesidioblastosis)---literature review.
        Pol J Pathol. 2017; 68: 97-101
        • Makuc J.
        Management of pancreatogenic diabetes: Challenges and solutions.
        Diabetes Metab Syndr Obes. 2016; 9: 311-315
        • Bhattamisra S.K.
        • Siang T.C.
        • Rong C.Y.
        • et al.
        Type-3c diabetes mellitus, diabetes of exocrine pancreas---an update.
        Curr Diabetes Rev. 2019; 15: 382-394
        • Wu L.
        • Nahm C.B.
        • Jamieson N.B.
        • et al.
        Risk factors for development of diabetes mellitus (Type 3c) after partial pancreatectomy: A systematic review.
        Clin Endocrinol (Oxf). 2020; 92: 396-406
        • Battelino T.
        • Danne T.
        • Bergenstal R.M.
        • et al.
        Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the International Consensus on Time In Range.
        Diabetes Care. 2019; 42: 1593-1603
        • Collyns O.J.
        • Meier R.A.
        • Betts Z.L.
        • et al.
        Improved glycemic outcomes with Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes.
        Diabetes Care. 2021; 44: 969-975
        • Beato-Vibora P.I.
        • Gallego-Gamero F.
        • Ambrojo-Lopez A.
        • et al.
        Rapid improvement in time in range after the implementation of an advanced hybrid closed-loop system in adolescents and adults with type 1 diabetes.
        Diabetes Technol Ther. 2021; 23: 609-615
        • Da Silva J.
        • Lepore G.
        • Battelino T.
        • et al.
        Real-world Performance of the MiniMed™ 780G System: First report of outcomes from 4'120 users.
        Diabetes Technol Ther. 2021; 24: 113-119
        • Farrington C.
        Psychosocial impacts of hybrid closed-loop systems in the management of diabetes: A review.
        Diabet Med. 2018; 35: 436-449
        • Niwano F.
        • Hiromine Y.
        • Noso S.
        • et al.
        Insulin deficiency with and without glucagon: A comparative study between total pancreatectomy and type 1 diabetes.
        J Diabetes Investig. 2018; 9: 1084-1090
        • Juel C.T.B.
        • Dejgaard T.F.
        • Hansen C.P.
        • et al.
        Glycemic control and variability of diabetes secondary to total pancreatectomy assessed by continuous glucose monitoring.
        J Clin Endocrinol Metab. 2021; 106: 168-173
        • Lee V.T.Y.
        • Poynten A.
        • Depczynski B.
        Continuous glucose monitoring to assess glucose variability in type 3c diabetes.
        Diabet Med. 2022; 39e14882
        • Rizzi A.
        • Tartaglione L.
        • Di Leo M.
        • Alfiere S.
        • Pitoco D.
        Advanced hybrid closed-loop system: First successful clinical case after total pancreatectomy.
        Acta Diabetol. 2021; 58: 967-969
        • Sherwood J.S.
        • Jafri R.Z.
        • Balliro C.A.
        • et al.
        Automated glycemic control with the bionic pancreas in cystic fibrosis-related diabetes: A pilot study.
        J Cyst Fibros. 2020; 19: 159-161
        • Scully K.J.
        • Palani G.
        • Zheng H.
        • Moheet A.
        • Putman M.S.
        The effect of Control IQ hybrid closed loop technology on glycemic control in adolescents and adults with cystic fibrosis-related diabetes.
        Diabetes Technol Ther. 2022; 24: 446-452